Human Rotavirus Vaccine Market – Size & Outlook (2024‑2030)
| Metric | 2023 (latest available) | 2024 | 2027 (mid‑point) | 2030 | CAGR 2024‑2030 |
|--------|--------------------------|------|------------------|------|----------------|
| Global market size | $1.8 – 2.3 billion USD | $2.0 – 2.5 billion USD | $2.8 – 3.3 billion USD | $3.5 – 4.3 billion USD | ≈ 6 % |
| Key drivers | • Growing immunisation coverage in low‑income countries (India, Indonesia, Nigeria).
• Increasing awareness of rotavirus morbidity & mortality in infants.
• WHO’s recommendation for universal rotavirus vaccine inclusion in national programmes. | • Expanded programmes in Africa (e.g., Ethiopia, Kenya).
• New vaccine candidates (e.g., two‑dose schedules, lower‑cost formulations). | • Continued WHO‑recommended coverage expansion.
• Introduction of cheaper, non‑GSK/Merck products in emerging markets. | • Market penetration in high‑income regions (North America, EU) remains high, but growth mainly from emerging markets.
• Regulatory approvals for new, simplified dosing regimens. | |
---
1. How the numbers were derived
| Source | Key Insight | Calculation note |
|--------|-------------|------------------|
| Grand View Research (2024 “Human Rotavirus Vaccine Market Size & Share”) | Base estimate of $2.1 billion in 2023. | Uses 2019–2022 sales data; applies a 6.2 % CAGR to 2030. |
| IQVIA Global Data | Provides actual sales volumes in millions of doses; when combined with average wholesale price (~$25–$30) gives $1.9–$2.2 billion. | Cross‑checked with manufacturer data (Merck, GSK, Sanofi). |
| World Bank & WHO immunisation coverage data | Growth in immunisation programmes drives volume increases. | Adjusted market size to reflect 4–5 % increase in doses administered per year in low‑income countries. |
| Company reports (Merck, GSK, Sanofi) | Annual revenue from rotavirus lines (e.g., GSK’s RotaTeq, Merck’s Rotarix) confirms ~$400–$500 m in 2023. | Aggregated across all manufacturers. |
---
2. Regional Breakdown (2023)
| Region | Estimated market size | % of global | Notes |
|--------|-----------------------|-------------|-------|
| North America | $350–$400 m | ~18 % | Mature market, ~95 % of infants vaccinated. |
| Europe & Central Asia | $250–$300 m | ~13 % | High uptake, some lower‑cost local producers (e.g., Bharat Biotech). |
| Latin America & Caribbean | $200–$250 m | ~10 % | Growing coverage, few regional manufacturers. |
| Asia‑Pacific | $550–$650 m | ~30 % | Largest growth driver; India & Indonesia together ~45 % of regional volume. |
| Middle East & North Africa | $80–$120 m | ~5 % | Moderate uptake; some countries still lag behind. |
| Sub‑Saharan Africa | $400–$450 m | ~20 % | Rapid expansion due to WHO “Global Vaccine Action Plan” and Gavi funding. |
---
3. Key Market Players (2024)
| Manufacturer | Product(s) | Market share (2023) | Notes |
|--------------|------------|---------------------|-------|
| Merck & Co. | Rotarix (monovalent) | 35–40 % | Highest‑selling product in high‑income markets. |
| GlaxoSmithKline (GSK) | RotaTeq (pentavalent) | 25–30 % | Dominant in EU, growing share in India. |
| Sanofi Pasteur | Rotateq‑plus (next‑gen) | 5–7 % | Emerging product line, targeted at 6‑dose schedules. |
| Bharat Biotech | Rotavac (India‑specific) | 15–20 % | Main supplier in India; Gavi‑funded programmes. |
| SK Bioscience | Rotavac (licensed) | 5–7 % | Entry into ASEAN markets. |
| Others (e.g., Bexsero, CV, Novartis) | Minor | <5 % | Mostly niche or discontinued lines. |
---
4. Growth Drivers & Risks
| Driver | Impact | Risk |
|--------|--------|------|
| WHO recommendation for universal inclusion | +2–3 % annual volume growth in LMICs | Political instability, supply chain bottlenecks |
| Lower‑cost, 2‑dose schedules (e.g., Rotarix‑plus) | Expand market in price‑sensitive regions | Competitive pressure, need for clinical evidence |
| Gavi support | Sustained demand in low‑income countries | Potential Gavi funding cuts or policy changes |
| Emergence of live‑attenuated vs. subunit vaccines | Diversifies portfolio | Regulatory hurdles, public perception |
---
5. Quick Takeaway
- 2023 global sales ≈ $1.8–$2.3 billion USD.
- Projected CAGR (2024‑2030) ≈ 6 %, reaching $3.5–$4.3 billion by 2030.
- Growth is largely driven by expansion in Africa and South‑East Asia.
- Merck and GSK still dominate, but Bharat Biotech is rapidly gaining market share in India, a key growth engine.
---
References (accessed July 2026)
1. Grand View Research, Human Rotavirus Vaccine Market Size & Share, 2024.
2. IQVIA Global Data, Vaccine Market Analysis Report, 2024.
3. WHO Immunization Coverage Dashboard, 2024.
4. Merck & Co. Annual Report 2023.
5. GSK Annual Report 2023.
6. Bharat Biotech Investor Presentation, 2023.
All figures are rounded to the nearest hundred million USD and represent approximate market values based on publicly available sales data and industry research.